Two Biotech Stocks with High Upside Potential: Viking Therapeutics and Recursion Pharmaceuticals

Viking Therapeutics and Recursion Pharmaceuticals are two clinical-stage biotechs with potential for massive upside. Viking is developing VK2735 for weight loss, with a market potential of $7.5 billion if it can grab 5% of the expected $150 billion anti-obesity market by 2035. Recursion Pharmaceuticals aims to revolutionize the drug development process with its AI-powered platform. Both biotechs have outperformed the market this year, but there's also risk involved.